



## FOR IMMEDIATE RELEASE

July 22, 2024

### **OncoGenesis, Inc. Names Jovelle Fernandez, MD/PhD as CEO/President**

*Internationally recognized OB/GYN and healthcare businesswoman executive  
to lead company's growth*

OncoGenesis, Inc. ("OncoGenesis") announced today that after an extensive search, it has named industry leader Dr. Jovelle Fernandez, MD, PhD as Chief Executive Officer and President.

"With a background in both direct patient care and research around the world, Dr. Fernandez is perfectly suited to complete the company's next funding round and bring its products into the market worldwide. She has hands-on experience with patients and regulatory bodies, as well as an extensive network aligned with Oncogenesis' globalization strategy to advance self-directed cervical cancer screening on a global basis," said Founder and Board Chair Peter Gombrich.

Dr. Fernandez is a board-certified Obstetrician & Gynecologist with subspecialty in Oncology, and expertise in molecular biology, HPV and cervical cancer. She is an award-winning executive and author with over 3 decades of experience in healthcare, academia, and the pharmaceutical and biotechnology industries. She has co-authored more than 60 scientific publications including topics involving women's health notably HPV vaccines, and cervical cancer screening. Her success in leading clinical development, R & D, and Medical Affairs at global, regional, and national levels while at major pharma companies, GSK and Takeda will accelerate OncoGenesis' paths into key markets. Dr. Fernandez is also the co-founder of several oncology therapeutic companies, where she helped secure funding for clinical trials and accelerate cancer drug access in low- and middle-income countries.

OncoGenesis' has secured multiple patents that provide solution to women around the world for self-sampling device and product platform to enable effective, fast, accessible, and affordable cervical screening. The self-sampling device, iPaP, can collect both cytology and HPV specimens. In addition, the self-collected sample from the iPaP can be introduced into the CerMark platform that utilizes rapid biomolecular analysis with results within minutes at the point of care. The CerMark platform screens not only HPV but more importantly, cervical disease without the requirement of a laboratory, sophisticated equipment, or complicated training for interpretation and analysis of results.



“I am excited to take on the role as the new CEO of Oncogenesis. I am honored to be a part of a highly motivated team dedicated to eliminating cervical cancer. I believe that CerMark offers an invaluable solution to women regardless of where they live, whereby they can collect cervical samples by themselves using the iPap, immediately know whether they have cervical disease or not, and receive optimal and prompt treatment potentially eliminating cervical cancer,” stated Dr. Fernandez.

The specimens collected from the iPap for both cytology and HPV testing have been demonstrated to be comparable to that collected by a physician. iPap is CE (European Conformity) marked and is available for sale and research in certain markets. CerMark and its assay are in multiple phases of development, and with the company’s development partner and funding, will be initiating clinical studies to obtain regulatory clearance.

Dr. Fernandez’s expertise has been sought globally, including at the World Economic Forum 4th Industrial Revolution. She is a Visiting Professor at Kobe University, Japan, where she obtained her PhD and post-doc. Dr. Fernandez completed her BS and MD degrees at Saint Louis University, Philippines. She is an alum of the University of Pennsylvania Wharton School of Business and Oxford University Said Business School, and she obtained various healthcare executive leadership and business certifications from INSEAD, Rotterdam School of Management, and Harvard Medical School.

**About OncoGenesis, Inc.:**

OncoGenesis is on a mission to help eliminate cervical cancer with early detection of HPV and cervical disease using effective, fast, accessible and affordable platform thereby enabling prompt treatment.

For inquiries or more information, please contact:

**Media Inquiries:** [Media@Oncogenx.com](mailto:Media@Oncogenx.com)

**Investor Relations:** [InvestorRelations@Oncogenx.com](mailto:InvestorRelations@Oncogenx.com)